Tonix Pharmaceuticals
TNXP
81 hedge funds and large institutions have $67M invested in Tonix Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 31 increasing their positions, 16 reducing their positions, and 8 closing their positions.
150% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 8
94% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 16
27% more call options, than puts
Call options by funds: $2.36M | Put options by funds: $1.85M
16% more funds holding
Funds holding: 70 → 81 (+11)
14% more capital invested
Capital invested by funds: $58.5M → $67M (+$8.48M)
4.54% more ownership
Funds ownership: 31.78% → 36.32% (+4.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$7.22M |
| 2 |
Millennium Management
New York
|
+$3.03M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.17M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.16M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.61M |
| 2 |
DKCM
Davidson Kempner Capital Management
New York
|
-$1.41M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$1.15M |
| 4 |
Jane Street
New York
|
-$471K |
| 5 |
Morgan Stanley
New York
|
-$381K |
TNXP Hedge Fund Activity: Q1 2026 in Review
81 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q1 2026, worth a combined $67M — up 14% from $58.5M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TNXP positions and 8 closed out — a net gain of 12 holders — while 31 added to existing stakes and 16 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $7.22M. The largest seller was Point72 Asset Management, cutting an estimated $7.61M.
- 81 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q1 2026, up from 70 in Q4 2025.
- Funds reported $67M of Tonix Pharmaceuticals stock for Q1 2026, up 14% quarter-over-quarter.
- 20 funds opened new Tonix Pharmaceuticals positions in Q1 2026 and 8 closed out, a net change of +12 holders.
- The largest Tonix Pharmaceuticals buyer in Q1 2026 was Citadel Advisors, an estimated $7.22M added.
- The largest Tonix Pharmaceuticals seller in Q1 2026 was Point72 Asset Management, an estimated $7.61M sold.
Based on aggregated 13F filings for Q1 2026.